Full-Time
Clinical-stage neurological disorder therapeutics developer
$147.6k - $186.6k/yr
Boston, MA, USA + 1 more
More locations: Needham, MA, USA
Hybrid
Two on-site days per week are required in Boston-area positions.
Bachelor's, Master's
See people who can refer or advise you
Xenon develops therapies for neurological disorders, especially epilepsy, in a clinical-stage biopharma setting, using research, partnerships, and licensing to move candidates toward commercialization. Its products are designed to act on neurological and genetic targets, with XEN007 in Phase 2 for treatment-resistant pediatric absence epilepsy illustrating its development pathway and reliance on clinical testing. The company differentiates itself by focusing on genetics-informed neurology and a pediatric, targeted epilepsy pipeline supported by collaborations rather than broad, one-size-fits-all approaches. The goal is to discover, develop, and eventually bring to patients therapies that address unmet neurological needs, advancing outcomes through a strong clinical pipeline and strategic partnerships.
Company Size
201-500
Company Stage
IPO
Headquarters
Burnaby, Canada
Founded
1996
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Short-& Long-term Disability
Accidental Death & Dismemberment
Life Insurance
Employee Assistance Program
401(k) Company Match
Stock Options
Tuition Reimbursement
Paid Vacation
Paid Sick Leave
Xenon Pharmaceuticals reported a second-quarter loss of $110.7 million, or $1.11 per share, beating analyst expectations. The Burnaby, British Columbia-based company performed better than the average estimate of seven analysts surveyed by Zacks Investment Research, who had predicted a loss of $1.16 per share.
Xenon Pharmaceuticals has reported positive Phase 3 X-TOLE2 data for azetukalner, its lead epilepsy candidate, and plans to submit a New Drug Application to the FDA in the third quarter of 2026. The company posted a first-quarter 2026 net loss of $102.3 million, or $1.17 per share. The biotech firm raised $837.6 million in equity financing, bringing cash and marketable securities to approximately $1.34 billion. Management expects this will fund operations into 2029, supporting late-stage trials and commercial launch preparations. The strengthened balance sheet reduces financing risk whilst the company remains pre-revenue. Xenon's narrative projects $284.9 million in revenue and $45.7 million in earnings by 2028, requiring 236.2% annual revenue growth. The most optimistic analysts forecast revenue reaching $905 million by 2029.
Xenon Pharmaceuticals chief medical officer Christopher John Kenney sold 1,410 common shares for approximately $78,000 on 13 March 2026, according to an SEC filing. The sale represented 16.63% of his direct holdings. The transaction stemmed from vested restricted share units that delivered 3,750 common shares, with 1,410 immediately sold to cover tax obligations through a routine sell-to-cover instruction. Following the sale, Kenney retains 7,069 directly held shares and 11,250 restricted share units. Xenon Pharmaceuticals develops clinical-stage therapeutics for neurological disorders, with a market capitalisation of $5 billion. The stock has risen 55% over the past year. The company generates revenue primarily through licensing and collaboration agreements, reporting $7.50 million in trailing twelve-month revenue.
Xenon raises USD 747.5m in upsized offering to fund Phase III azetukalner programs. March 13, 2026 Canada-based Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company with offices in Vancouver and Boston, announced the closing of an upsized underwritten public offering generating approximately USD 747.5 million in gross proceeds before expenses. The capital raise comes as the company advances its lead asset, azetukalner, through multiple Phase III clinical programs across epilepsy and psychiatric indications, requiring funding for late-stage development and potential commercialization activities. The offering consisted of 12,236,843 common shares priced at USD 57.00 per share, and included 1,710,526 additional shares issued upon the full exercise of the underwriters' option to purchase additional shares. Xenon also issued pre-funded warrants to purchase up to 877,194 common shares at a price of USD 56.9999 per warrant. J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair served as joint book-running managers. Company overview and pipeline. Xenon Pharmaceuticals' lead molecule, azetukalner (XEN1101), is a KV7 potassium channel opener currently in Phase III clinical development. The compound is being evaluated in multiple indications: a Phase III trial in primary generalized tonic-clonic seizures (the X-ACKT study) is currently recruiting with a target enrollment of 160 patients across sites in the United States, Australia, and Mexico. Azetukalner is also being studied in a Phase III open-label extension trial in bipolar I or II depression (X-CEED-OLE), which is enrolling by invitation with a target of 400 participants. Additional Phase II trials evaluating azetukalner as adjunctive therapy in focal epilepsy have been conducted across sites in Canada, the United States, Moldova, the United Kingdom, Ukraine, and Spain. The company's earlier-stage pipeline includes KV7 and NaV1.7 ion channel modulators in Phase I development for potential treatment of pain. On the business development side, Xenon maintains an ongoing license and collaboration agreement with Neurocrine Biosciences (Nasdaq: NBIX), originally established in 2019, covering NaV1.6 sodium channel inhibitors for epilepsy. That deal included a USD 50 million upfront payment and up to USD 1.7 billion in potential milestone payments, of which USD 25 million in regulatory milestones had been achieved as of the most recent available disclosures. Your email address will not be published. Required fields are marked *
Xenon Pharmaceuticals has surged 37.1% over the past week and 39% over the past month, prompting valuation concerns. The neuroscience-focused biopharmaceutical company is developing therapies for neurological and psychiatric disorders, with lead candidate Azetukalner in Phase 3 trials for epilepsy and early stage programmes targeting pain and mood disorders. Trading at $59.04 per share, Xenon appears slightly overvalued compared to a narrative fair value of $55.40. The company remains loss-making with modest revenue of $7.5 million, though analyst targets suggest potential upside. The valuation narrative assumes rapid revenue expansion and improved margins as Azetukalner expands into major depressive disorder and bipolar depression. However, late-stage trial setbacks or unfavourable reimbursement terms could challenge these projections.